Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) Price Target at $32.64

Aardvark Therapeutics, Inc. (NASDAQ:AARD) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $32.6364.

AARD has been the subject of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Aardvark Therapeutics in a research report on Monday, December 29th. Royal Bank Of Canada cut their price objective on shares of Aardvark Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday, November 14th. BTIG Research reaffirmed a “buy” rating and issued a $26.00 target price on shares of Aardvark Therapeutics in a report on Tuesday. Raymond James Financial reiterated a “strong-buy” rating and set a $47.00 target price on shares of Aardvark Therapeutics in a research report on Monday, January 12th. Finally, William Blair started coverage on Aardvark Therapeutics in a research report on Friday, December 12th. They issued an “outperform” rating for the company.

Insider Activity at Aardvark Therapeutics

In other news, CEO Tien-Li Lee bought 7,000 shares of Aardvark Therapeutics stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average cost of $14.48 per share, with a total value of $101,360.00. Following the acquisition, the chief executive officer owned 1,551,613 shares of the company’s stock, valued at $22,467,356.24. The trade was a 0.45% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Nelson Sun purchased 3,000 shares of the stock in a transaction on Thursday, December 11th. The shares were purchased at an average cost of $14.40 per share, for a total transaction of $43,200.00. Following the acquisition, the chief financial officer directly owned 108,484 shares of the company’s stock, valued at approximately $1,562,169.60. This represents a 2.84% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Aardvark Therapeutics in the 2nd quarter worth $42,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Aardvark Therapeutics during the fourth quarter worth about $47,000. New York State Common Retirement Fund bought a new stake in Aardvark Therapeutics during the 2nd quarter valued at approximately $99,000. MetLife Investment Management LLC bought a new stake in Aardvark Therapeutics during the 4th quarter valued at approximately $102,000. Finally, Bank of America Corp DE lifted its holdings in Aardvark Therapeutics by 72.9% in the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock worth $108,000 after purchasing an additional 3,369 shares in the last quarter.

Aardvark Therapeutics Stock Performance

AARD stock opened at $12.28 on Tuesday. The company has a market cap of $267.34 million and a price-to-earnings ratio of -5.79. The business’s 50-day moving average is $13.92 and its two-hundred day moving average is $12.16. Aardvark Therapeutics has a fifty-two week low of $4.88 and a fifty-two week high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.07.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.